M D Galsky

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. ncbi The role of taxanes in the management of bladder cancer
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Oncologist 10:792-8. 2005
  2. ncbi Docetaxel-based combination therapy for castration-resistant prostate cancer
    M D Galsky
    Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89169, USA
    Ann Oncol 21:2135-44. 2010
  3. ncbi Outcomes and prognosis in advanced renal cell carcinoma
    Matthew D Galsky
    Genitourinary Oncology Program, US Oncology Research, Las Vegas, Nevada, USA
    Expert Rev Anticancer Ther 7:839-45. 2007
  4. ncbi Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics
    Matthew D Galsky
    Translational Oncology Program, US Oncology Research, Dallas, TX, USA
    Invest New Drugs 28:194-8. 2010
  5. ncbi Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:549-55. 2007
  6. ncbi Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
    G Sonpavde
    Texas Oncology and US Oncology Research, Houston, TX, USA
    Ann Oncol 23:1803-8. 2012
  7. ncbi Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
    G Sonpavde
    US Oncology Research, Inc, Houston, TX, USA
    Ann Oncol 21:319-24. 2010
  8. ncbi Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008
  9. ncbi Current optimal chemotherapy for advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research and Texas Oncology PA, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Rev Anticancer Ther 8:51-61. 2008
  10. ncbi Patient selection for phase II trials
    Guru Sonpavde
    Texas Oncology, P A, Dallas, Texas, USA
    Am J Clin Oncol 32:216-9. 2009

Detail Information

Publications26

  1. ncbi The role of taxanes in the management of bladder cancer
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Oncologist 10:792-8. 2005
    ....
  2. ncbi Docetaxel-based combination therapy for castration-resistant prostate cancer
    M D Galsky
    Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89169, USA
    Ann Oncol 21:2135-44. 2010
    ..To improve outcomes, numerous studies have evaluated docetaxel in combination with other agents. Here, results for docetaxel-based combination therapy in castration-resistant prostate cancer (CRPC) are reviewed...
  3. ncbi Outcomes and prognosis in advanced renal cell carcinoma
    Matthew D Galsky
    Genitourinary Oncology Program, US Oncology Research, Las Vegas, Nevada, USA
    Expert Rev Anticancer Ther 7:839-45. 2007
    ..This review will focus on studies that define the outcome and prognosis in advanced renal cell carcinoma...
  4. ncbi Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics
    Matthew D Galsky
    Translational Oncology Program, US Oncology Research, Dallas, TX, USA
    Invest New Drugs 28:194-8. 2010
    ..To describe a phase II study design to evaluate the activity of novel anti-cancer agents that focuses on molecular pathogenesis rather than tumor histology...
  5. ncbi Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:549-55. 2007
    ..The safety and activity of a dose-dense carboplatin-based regimen in this patient population were explored...
  6. ncbi Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
    G Sonpavde
    Texas Oncology and US Oncology Research, Houston, TX, USA
    Ann Oncol 23:1803-8. 2012
    ..A randomized, double-blind, placebo-controlled phase II trial compared DP combined with either AT-101 (A) or placebo in chemonaive mCRPC...
  7. ncbi Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
    G Sonpavde
    US Oncology Research, Inc, Houston, TX, USA
    Ann Oncol 21:319-24. 2010
    ..This phase II trial evaluated sunitinib malate in patients with progressing metastatic CRPC following prior docetaxel...
  8. ncbi Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
  9. ncbi Current optimal chemotherapy for advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research and Texas Oncology PA, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Rev Anticancer Ther 8:51-61. 2008
    ..The profusion of novel biologic agents offers the promise of improved outcomes. A multidisciplinary approach is necessary to make therapeutic advances...
  10. ncbi Patient selection for phase II trials
    Guru Sonpavde
    Texas Oncology, P A, Dallas, Texas, USA
    Am J Clin Oncol 32:216-9. 2009
    ..Such trials may be superior guides to select regimens for further development than trials that are single-center based with favorable populations...
  11. ncbi Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
    Guru Sonpavde
    Texas Oncology, Baylor College of Medicine, Houston, TX 77598, USA
    Lancet Oncol 11:861-70. 2010
    ..A multidisciplinary approach is necessary to make therapeutic advances. This review discusses current second-line therapy and emerging drugs for advanced transitional-cell carcinoma...
  12. ncbi Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy
    Robert Jotte
    Rocky Mountain Cancer Centers, 10103 Ridgegate Pkwy G 01, Lone Tree, CO 80124, USA
    J Clin Oncol 29:287-93. 2011
    ..This phase II study evaluated the safety and efficacy of single-agent amrubicin versus topotecan in patients with small-cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy...
  13. ncbi Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
    Matthew D Galsky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1439-46. 2005
    ..To evaluate the antitumor activity and safety of the epothilone B analog, ixabepilone, with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer...
  14. ncbi Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
    Guru Sonpavde
    Genitourinary Oncology Program, U S Oncology Research, Houston, Texas, USA
    Cancer 110:2628-39. 2007
    ..Recent and ongoing studies of neoadjuvant therapy followed by prostatectomy were reviewed...
  15. ncbi Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  16. ncbi Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials
    Thomas E Hutson
    Genitourinary Oncology Program, Texas Oncology, PA, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Genitourin Cancer 5:S31-9. 2006
    ..Combinations of these agents are being evaluated. Clinical trials designed to further assess these and other agents need to be vigorously supported...
  17. ncbi Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
    Matthew D Galsky
    Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2147-54. 2008
    ..This novel immunoconjugate has shown cytotoxic anti-prostate cancer activity. This study investigated the safety profile, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MLN2704...
  18. ncbi Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors
    M D Galsky
    Division of Hematology Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai School of Medicine, New York 10029, USA
    Ann Oncol 23:1037-44. 2012
    ..The current study was designed to evaluate the effect of varying degrees of renal impairment on the safety and pharmacokinetics (PKs) of satraplatin...
  19. ncbi Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    Invest New Drugs 25:265-70. 2007
    ..The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma...
  20. ncbi Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
    Atreya Dash
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:506-13. 2006
    ..This finding is most striking in the elderly. Better selection of patients who may safely receive cisplatin and more effective regimens devoid of cisplatin are required to optimize outcomes in this group of patients...
  21. ncbi Violaceous exanthem as a manifestation of metastatic prostate cancer in skin
    Susan F Slovin
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Urology 67:420. 2006
  22. ncbi Problems with the randomized discontinuation design
    Guru Sonpavde
    J Clin Oncol 24:4669-70; author reply 4670-1. 2006
  23. ncbi Germ-cell tumors
    Varuni Kondagunta
    N Engl J Med 357:1773; author reply 1773-4. 2007
  24. ncbi A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy
    Jonathan E Rosenberg
    Division of Hematology Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 106:58-62. 2006
    ..Clinical cross-resistance of ixabepilone and taxanes in HRPC is unknown...
  25. ncbi Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?
    Matthew D Galsky
    J Clin Oncol 23:4823-6. 2005
  26. ncbi Trial design for metastatic castration-resistant prostate cancer
    Guru Sonpavde
    J Clin Oncol 26:3647-8; author reply 3648-9. 2008